Literature DB >> 994669

[Surgical treatment of malignant melanoma (author's transl)].

A Encke, A Best.   

Abstract

The primary lesion is widely excised under a general anesthetic. The resulting defect is covered by a free graft. Prophylactic lymph-node dissection seems to be reasonable for stage-I melanoma with deep invasion (microstage III-V) according to recent investigations. Stage II is an absolute indication. Stage III patients received an individual palliative therapy. The value of additional measures is not yet clearly defined.

Entities:  

Mesh：

Year:  1976        PMID： 994669     DOI： 10.1007/bf01267421

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN： 0023-8236


  10 in total

1.  REMOVAL OF FASCIA--CAUSE OF MORE FREQUENT METASTASES OF MALIGNANT MELANOMAS OF THE SKIN TO REGIONAL LYMPH NODES?

Authors:  G OLSEN
Journal:  Cancer       Date:  1964-09       Impact factor: 6.860

2.  [Treatment of malignant melanoma (clinical stages I and II) (author's transl)].

Authors:  J Tonak; P Hermanek; O P Hornstein; F Weidner
Journal:  Dtsch Med Wochenschr       Date:  1976-03-19       Impact factor: 0.628

3.  The role of groin dissection in the management of melanoma of the lower extremity.

Authors:  J G McCarthy; C D Haagensen; F P Herter
Journal:  Ann Surg       Date:  1974-02       Impact factor: 12.969

4.  The role of frozen section in the diagnosis and management of malignant melanoma.

Authors:  N C Davis; J H Little
Journal:  Br J Surg       Date:  1974-07       Impact factor: 6.939

5.  Selective regional lymphadenectomy for melanoma: a mathematical aid to clinical judgment.

Authors:  H C Polk; B S Linn
Journal:  Ann Surg       Date:  1971-09       Impact factor: 12.969

6.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

7.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

Authors:  W H Clark; L From; E A Bernardino; M C Mihm
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

8.  Biopsy and prognosis of malignant melanoma.

Authors:  E Epstein; K Bragg; G Linden
Journal:  JAMA       Date:  1969-05-26       Impact factor: 56.272

9.  Malignant melanoma of the extremities: a clinicopathologic study using levels of invasion (microstage).

Authors:  H J Wanebo; J Woodruff; J G Fortner
Journal:  Cancer       Date:  1975-03       Impact factor: 6.860

10.  BCG immunotherapy of malignant melanoma: summary of a seven-year experience.

Authors:  D L Morton; F R Eilber; E C Holmes; J S Hunt; A S Ketcham; M J Silverstein; F C Sparks
Journal:  Ann Surg       Date:  1974-10       Impact factor: 12.969
  10 in total
  1 in total

1.  Therapeutic and clinico-pathological factors in the survival of 1,469 patients with primary cutaneous malignant melanoma in clinical stage I. A multivariate regression analysis.

Authors:  K Søndergaard; G Schou
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.